We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Industry

Image: The collaboration between Heidelberg Epignostix and the NHS Genomic Medicine Service (GMS) establishes a national framework spanning each of the NHS GMS Genomic Laboratory testing service. (Image Credit: Heidelberg Epignostix)

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers

A new partnership now brings clinically validated epigenetic tumor classifiers into NHS genomic laboratory services across England.  More...
02 Sep 2026
Image: The Lumipulse G NfL Blood assay provides a reliable method for the quantitative measurement of neurofilament light chain NfL in serum and plasma (Photo courtesy of Fujirebio)

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada

Health Canada has issued Class II Medical Device Licenses for Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma on the fully automated LUMIPULSE G platform. More...
02 Sep 2026
Image:  About 14.2 million Americans are eligible for annual lung cancer screening, but uptake remains low and LDCT false positives persist; CIZ1B may improve risk stratification and reduce uncertainty (Image Credit: Adobe Stock)

Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment

Cizzle Bio’s CIZ1B ELISA biomarker test detects an early lung cancer-linked protein variant, complementing low-dose CT to clarify indeterminate findings. More...
01 Sep 2026
Image: Natera’s Signatera test will be used in a partnership with Angiex to evaluate patients receiving AGX101, a Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) in a Phase I clinical trial.

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial

Natera’s Signatera test will be used to evaluate patients receiving Angiex’s nuclear-delivered antibody-drug conjugate in a Phase I trial. More...
31 Aug 2026
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

A tumor-informed ctDNA MRD assay gains expanded coverage to monitor immunotherapy response in late-stage solid tumors. More...
28 Aug 2026
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

A new pair of companion diagnostics expands HER2 testing in metastatic gastroesophageal cancer. More...
27 Aug 2026
Image Credit: Adobe Stock

Global Urinalysis Market Gowth Driven by Demand for Automated and POC Testing

The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031. More...
26 Aug 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.


LabMedica Industry News channel reports on mergers and takeovers, on cooperative agreements and on trends in the IVD industry worldwide.
Copyright © 2000-2026 Globetech Media. All rights reserved.